Durect Corp [DRRX]

Source: 

Company Overview

We are a biopharmaceutical company advancing novel and potentially lifesaving investigational therapies derived from our Epigenetic Regulator Program.DUR928, a new chemical entity in clinical development, is the lead candidate in our Epigenetic Regulator Program.An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival.